Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker GKOS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | iDose TR Administration in an Office-Based Surgery Setting NCT07816692 · Open Angle Glaucoma (OAG), Ocular Hypertension (OHT) iDose TR (travoprost intracameral implant) 75 µg | GKOS Glaukos Corporation | — | Recruiting | 30 | Mar 2027 | Registry ↗ |
| Sep 17, 2026 | Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral… NCT07075718 · Glaucoma Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.… | GKOS Glaukos Corporation | Phase 2 | Recruiting | 110 | Mar 2028 | Registry ↗ |
| Jun 5, 2026 | Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for K… NCT07629557 · Keratoconus Riboflavin Ophthalmic Solutions, UV-A Irradiation System | GKOS Glaukos Corporation | Phase 4 | Recruiting | 15 | Sep 2027 | Registry ↗ |
| Jun 2, 2026 | Travoprost Intraocular Implant + iStent Infinite NCT06066645 · Glaucoma, Open-Angle Travoprost Intraocular Implant, iStent infinite | GKOS Glaukos Corporation | Phase 4 | Recruiting | 150 | May 2027 | Registry ↗ |
| Mar 30, 2026 | Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant NCT07495852 · Glaucoma Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.… | GKOS Glaukos Corporation | Phase 3 | Recruiting | 510 | Jun 2028 | Registry ↗ |
| Feb 27, 2026 | Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis NCT07400965 · Demodex Blepharitis GLK-321 low dose BID, GLK-321 mid dose BID | GKOS Glaukos Corporation | Phase 2 | Recruiting | 250 | Sep 2026 | Registry ↗ |
| Feb 27, 2026 | Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg NCT07400926 · Open Angle Glaucoma (OAG), Ocular Hypertension (OH) Travoprost | GKOS Glaukos Corporation | — | Recruiting | 30 | Jun 2026 | Registry ↗ |
| Feb 10, 2026 | Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subj… NCT07400952 · Keratoconus GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution | GKOS Glaukos Corporation | Phase 2 | Recruiting | 100 | Apr 2027 | Registry ↗ |
| Jan 21, 2026 | Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone NCT06848946 · Glaucoma, Open-angle, Ocular Hypertension (OHT) iDose TR (travoprost intracameral implant) 75 µg in conjunc… | GKOS Glaukos Corporation | Phase 4 | Recruiting | 132 | Aug 2026 | Registry ↗ |
| Jul 24, 2025 | A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects Wit… NCT05966493 · Persistent Corneal Epithelial Defect lufepirsen high dose, Vehicle | GKOS Glaukos Corporation | Phase 2 | Recruiting | 84 | Dec 2025 | Registry ↗ |
| Jul 14, 2025 | NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries NCT04081103 · Corneal Persistent Epithelial Defect Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lu… | GKOS Glaukos Corporation | Phase 2 | Terminated | 35 | Feb 7, 2022 | Registry ↗ |
| Nov 29, 2024 | Clinical Study Comparing Two Models of a Travoprost Intraocular Implant NCT03868124 · Glaucoma, Open-Angle, Ocular Hypertension G2-TR intraocular implant containing travoprost, Sham surge… | GKOS Glaukos Corporation | Phase 3 | Completed | 560 | Jun 10, 2022 | Registry ↗ |
| Nov 29, 2024 | Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha… NCT03519386 · Glaucoma, Open-Angle, Ocular Hypertension G2-TR intraocular implant containing travoprost, Sham surge… | GKOS Glaukos Corporation | Phase 3 | Completed | 590 | Apr 5, 2022 | Registry ↗ |
| Oct 15, 2024 | Performance of the Travoprost Intraocular Implant NCT06582732 · Glaucoma, Open-Angle, Ocular Hypertension Travoprost Intracameral Implant exchanged at Month 12, Trav… | GKOS Glaukos Corporation | Phase 2 | Completed | 210 | Nov 2, 2023 | Registry ↗ |
| Aug 15, 2024 | Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor NCT05127551 · Glaucoma, Glaucoma, Open-Angle iStent Infinite, Competitor Device | GKOS Glaukos Corporation | Not applicable | Unknown | 179 | Feb 29, 2024 | Registry ↗ |
| Jul 8, 2024 | Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus NCT05314738 · Progressive Keratoconus NXL Energy 1, NXL Energy 2 | GKOS Glaukos Corporation | Phase 1/2 | Unknown | 150 | Aug 2025 | Registry ↗ |
| Jun 3, 2024 | Travoprost Intraocular Implant in Conjunction With Cataract Surgery NCT06061718 · Open Angle Glaucoma, Ocular Hypertension iDose TR | GKOS Glaukos Corporation | Phase 3 | Unknown | 60 | Mar 18, 2024 | Registry ↗ |
| Feb 23, 2024 | iStent Inject New Enrollment Post-Approval Study NCT04624698 · Glaucoma, Open-Angle, Glaucoma iStent Inject Implantation | GKOS Glaukos Corporation | Not applicable | Unknown | 358 | May 2026 | Registry ↗ |
| Feb 23, 2024 | Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia A… NCT03319082 · Corneal Ectasia Corneal Collagen Cross-linking | GKOS Glaukos Corporation | — | Unknown | 200 | Feb 2026 | Registry ↗ |
| Jan 30, 2024 | Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive… NCT03442751 · Progressive Keratoconus Test Article A, Test Article B | GKOS Glaukos Corporation | Phase 3 | Completed | 201 | Nov 1, 2019 | Registry ↗ |
| Dec 6, 2023 | Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension NCT06152861 · Open Angle Glaucoma, Ocular Hypertension Travoprost Ophthalmic Topical Cream low-dose, Travoprost Op… | GKOS Glaukos Corporation | Phase 2 | Unknown | 250 | Aug 2024 | Registry ↗ |
| Sep 28, 2023 | Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary O… NCT06057051 · Glaucoma iStent Infinite | GKOS Glaukos Corporation | Not applicable | Recruiting | 245 | Aug 2025 | Registry ↗ |
| Sep 26, 2023 | Study of Exchange of Travoprost Intraocular Implant NCT04615403 · Open Angle Glaucoma Travoprost | GKOS Glaukos Corporation | Phase 2 | Completed | 33 | Feb 28, 2022 | Registry ↗ |
| Sep 26, 2023 | Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution NCT02754596 · Glaucoma Open-angle Travoprost Intraocular Implant, high elution, Travoprost In… | GKOS Glaukos Corporation | Phase 2 | Completed | 154 | Aug 1, 2017 | Registry ↗ |
| Sep 1, 2023 | Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia NCT05124275 · Presbyopia Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine O… | GKOS Glaukos Corporation | Phase 2 | Completed | 123 | Sep 6, 2022 | Registry ↗ |
| Jul 12, 2023 | Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease NCT05119920 · Dry Eye Disease, Kerato Conjunctivitis Sicca Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine O… | GKOS Glaukos Corporation | Phase 2 | Completed | 226 | Jul 27, 2022 | Registry ↗ |
| Dec 22, 2022 | Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty NCT02327312 · Primary Open-Angle Glaucoma Stents, Laser | GKOS Glaukos Corporation | Not applicable | Terminated | 91 | May 31, 2019 | Registry ↗ |
| Sep 9, 2022 | iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications NCT03478293 · Primary Open Angle Glaucoma (POAG) iStent inject surgery | GKOS Glaukos Corporation | Not applicable | Terminated | 6 | Dec 30, 2020 | Registry ↗ |
| Sep 9, 2022 | A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iS… NCT03255798 · Glaucoma, Open-Angle G2 and G3 | GKOS Glaukos Corporation | Not applicable | Terminated | 7 | Jun 6, 2019 | Registry ↗ |
| Sep 9, 2022 | Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iS… NCT03255785 · Glaucoma, Open-Angle Cataract surgery plus one iStent and one iStent Supra impla… | GKOS Glaukos Corporation | Not applicable | Completed | 15 | Dec 3, 2019 | Registry ↗ |
| Sep 8, 2022 | Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive… NCT02868190 · Open Angle Glaucoma Two trabecular micro-bypass stents (iStent inject) | GKOS Glaukos Corporation | Phase 4 | Completed | 57 | Nov 8, 2019 | Registry ↗ |
| Sep 8, 2022 | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medi… NCT01444040 · Open-angle Glaucoma iStent inject, Travoprost | GKOS Glaukos Corporation | Phase 4 | Completed | 196 | Mar 28, 2019 | Registry ↗ |
| Sep 7, 2022 | Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hyp… NCT02873806 · Open-angle Glaucoma Implantation of two iStent inject micro-bypass stents, Topi… | GKOS Glaukos Corporation | Phase 4 | Completed | 53 | Nov 8, 2019 | Registry ↗ |
| Sep 7, 2022 | Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoro… NCT01456390 · Open-Angle Glaucoma iStent and iStent supra | GKOS Glaukos Corporation | Not applicable | Completed | 79 | Mar 26, 2019 | Registry ↗ |
| Sep 7, 2022 | A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Tre… NCT01252914 · Subject With Primary Open-angle Glaucoma (POAG) iStent Supra Stent | GKOS Glaukos Corporation | Phase 4 | Completed | 80 | Dec 16, 2019 | Registry ↗ |
| Sep 7, 2022 | Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treate… NCT01252888 · Subjects With Primary Open-angle Glaucoma (POAG) iStents | GKOS Glaukos Corporation | Phase 4 | Completed | 39 | Jul 2016 | Registry ↗ |
| Aug 31, 2022 | One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects NCT01517477 · Primary Open Angle Glaucoma (POAG) iStent, iStent | GKOS Glaukos Corporation | Not applicable | Completed | 119 | Oct 18, 2019 | Registry ↗ |
| Aug 31, 2022 | Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One… NCT01455467 · Open-angle Glaucoma One iStent, Two iStent | GKOS Glaukos Corporation | Not applicable | Completed | 79 | Oct 18, 2019 | Registry ↗ |
| Aug 31, 2022 | Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two… NCT01444105 · Open-angle Glaucoma iStent, SLT | GKOS Glaukos Corporation | Not applicable | Completed | 80 | Apr 9, 2019 | Registry ↗ |
| Aug 31, 2022 | Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the… NCT01252849 · Primary Open Angle Glaucoma (POAG) iStent, iStent | GKOS Glaukos Corporation | Not applicable | Completed | 119 | Oct 8, 2019 | Registry ↗ |
| May 19, 2022 | Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injec… NCT01461291 · Primary Open-angle Glaucoma iStent inject, Cataract surgery | GKOS Glaukos Corporation | Not applicable | Completed | 505 | Aug 4, 2017 | Registry ↗ |
| May 19, 2022 | Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Catarac… NCT01461278 · Primary Open-angle Glaucoma iStent supra, Cataract surgery | GKOS Glaukos Corporation | Not applicable | Completed | 505 | Mar 13, 2019 | Registry ↗ |
| Oct 20, 2021 | iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study NCT04624685 · Glaucoma, Open-Angle | GKOS Glaukos Corporation | — | Unknown | 475 | Jan 20, 2021 | Registry ↗ |
| Oct 20, 2021 | Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Con… NCT01841450 · Primary Open Angle Glaucoma iStent, Cataract surgery | GKOS Glaukos Corporation | Not applicable | Unknown | 360 | Aug 2021 | Registry ↗ |
| Apr 26, 2021 | Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus NCT01972854 · Keratoconus riboflavin solution, placebo solution | GKOS Glaukos Corporation | Phase 3 | Terminated | 92 | Mar 2016 | Registry ↗ |
| Apr 26, 2021 | Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia an… NCT01893359 · Hyperopia, Hyperopic Astigmatism riboflavin ophthalmic solution, 0% dextran, UVA Irradiation… | GKOS Glaukos Corporation | Phase 1/2 | Terminated | 2 | Feb 2015 | Registry ↗ |
| Apr 26, 2021 | Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Ref… NCT01643252 · Corneal Ectasia riboflavin: 0.12% riboflavin ophthalmic solution with the K… | GKOS Glaukos Corporation | Phase 3 | Withdrawn | 0 | — | Registry ↗ |
| Apr 26, 2021 | Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus NCT01643226 · Keratoconus riboflavin solution, placebo solution | GKOS Glaukos Corporation | Phase 3 | Completed | 230 | Jul 2015 | Registry ↗ |
| Apr 26, 2021 | Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus NCT01344187 · Keratoconus riboflavin solution, placebo solution | GKOS Glaukos Corporation | Phase 3 | Completed | 236 | Jun 2015 | Registry ↗ |
| Apr 26, 2021 | Feasibility Study of the Vedera KXS for Treatment of Keratoconus NCT01069848 · Keratoconus Vedera KXS | GKOS Glaukos Corporation | Not applicable | Completed | 23 | Mar 2011 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances